You Can Lose Weight Without Regularly Using Medications Like Ozempic

Individuals using GLP-1 medications such as Ozempic can still achieve weight loss despite facing difficulties in obtaining their prescriptions.

Medications like Semaglutide, marketed under the names Ozempic and Wegovy, have transformed obesity treatment, yet the increasing demand has led to significant supply shortages. In the U.S., changes in insurance coverage for these drugs can lead to confusion. For instance, CVS Caremark, which assists insurers in managing their prescription plans, recently discontinued coverage for Eli Lilly’s Zepbound, linked to the GLP-1 drug tilzepatide.

To investigate the impact of this confusion, Kaelen Medeiros and a colleague from a New York firm analyzed data from over 6,000 participants in the U.S. who enrolled in their program for a year between 2021 and 2024.

The program provided access to an app delivering bi-weekly lessons aimed at optimizing lifestyle choices such as nutrition and physical activity. Additionally, participants enjoyed regular one-on-one consultations with a health coach who assisted in applying these lessons. For an extra charge, all participants received GLP-1 medications, like Ozempic, mainly on a weekly basis.

By the program’s conclusion, 73% of participants experienced at least one disruption in GLP-1 access, defined as missing the medication for a minimum of 13 weeks. These participants received, on average, eight months’ supply of GLP-1 over the year-long trial. Participants lost an average of 14% of their body weight, compared to a 17% reduction among those who did not face such disruptions. The findings were shared at the Endocrinology Society’s annual general meeting in San Francisco on July 14th.

A similar rate of weight loss was observed in the program’s second year, regardless of the consistency of GLP-1 supply. “Although this confusion is concerning, it’s encouraging to see significant clinically relevant weight loss achieved despite it,” Medeiros remarks.

“This study is promising,” says Priya Jaisinghani from NYU Langone Health, New York. However, further research is needed to assess how the health coaching and lifestyle lessons provided to participants influenced weight loss, she notes. The researchers didn’t measure the engagement levels of participants in this segment of the program. Medeiros pointed out that variations in adherence might have impacted the outcomes.

Some participants also took metformin, a medication for type 2 diabetes that can aid in weight loss. Nevertheless, metformin is associated with only about a 2% reduction in body weight.